Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Rep. Tauzin Ready To Negotiate With PhRMA After Resigning Committee Chair

  • News

Executive Summary

Rep. Billy Tauzin's resignation from the chairmanship of the Energy & Commerce Committee paves the way for negotiations to begin in earnest for him to take over as president of the Pharmaceutical Research & Manufacturers of America

You may also be interested in...



Energy & Commerce Health Chairman Deal Brings Medicaid Background

Rep. Nathan Deal (R-Ga.) brings Medicaid expertise to his new role as House Energy & Commerce Health Subcommittee chairman

Energy & Commerce Health Chairman Deal Brings Medicaid Background

Rep. Nathan Deal (R-Ga.) brings Medicaid expertise to his new role as House Energy & Commerce Health Subcommittee chairman

PhRMA CEO Selection Day Nears Now That Election Day Has Passed

The Pharmaceutical Research & Manufacturers of America is expected to finalize the succession plan for CEO Alan Holmer during its annual strategy session Nov. 11 and 12

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS043317

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By